Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2025-12-25 @ 4:41 AM
NCT ID:
NCT04176718
Brief Summary:
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.
This research study involves two study drugs and two standard of care drugs.
* The names of the study drugs involved in this study are:
* Carfilzomib
* Daratumumab
* The names of the standard of care drugs involved in this study are:
* Dexamethasone
* Pomalidomide
Detailed Description:
This phase II, multicenter, open-label study is studying daratumumab in combination with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma who have received at least one prior therapy and who have had previous treatment with both lenalidomide and a proteasome inhibitor.
* The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves two study drugs and two standard of care drugs.
* The names of the study drugs involved in this study are:
* Carfilzomib
* Daratumumab
* The names of the standard of care drugs involved in this study are:
* Dexamethasone
* Pomalidomide
* A total of 43 participants will be enrolled to this trial
* The U.S. Food and Drug Administration (FDA) has not approved Daratumumab, and Carfilzomib for use in treatment of Multiple Myeloma.
Study:
NCT04176718
Study Brief:
Protocol Section:
NCT04176718